Nature Communications (Jan 2022)

MAPK4 promotes triple negative breast cancer growth and reduces tumor sensitivity to PI3K blockade

  • Wei Wang,
  • Dong Han,
  • Qinbo Cai,
  • Tao Shen,
  • Bingning Dong,
  • Michael T. Lewis,
  • Runsheng Wang,
  • Yanling Meng,
  • Wolong Zhou,
  • Ping Yi,
  • Chad J. Creighton,
  • David D. Moore,
  • Feng Yang

DOI
https://doi.org/10.1038/s41467-021-27921-1
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 14

Abstract

Read online

PI3K inhibitors have limited efficacy in triple negative breast cancer (TNBC). Here, the authors show that MAPK4 activates AKT independent of PI3K and thus promotes tumour growth in a subset of TNBC and that MAPK4 inhibition sensitizes to PI3K blockade in these tumours.’